The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an ...

2025 年 6 月 2 日，法国制药巨头赛诺菲（Sanofi）宣布收购美国生物制药上市公司Blueprint Medicines，以扩大自身在罕见 免疫 疾病领域的产品组合，并增添免疫学领域的早期研发管线，交易总金额高达 95 亿美元。

赛诺菲（Sanofi）同意以高达95亿美元收购Blueprint Medicines，这是这家法国制药公司自出售其消费者健康业务控股权以来，最大的一笔交易，旨在补充其药品管线。

Blueprint, based in Cambridge, has an approved drug called Ayvakit that treats a rare immunological condition.

Sanofi has agreed to acquire US-based Blueprint Medicines for an equity value of $9.1bn to bolster its immunology pipeline ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...

{"articleTitle": "美股医疗保健股巨震！赛诺菲91亿美元收购Blueprint Medicines，市场将走向何方？", "articleContent": ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

L’operazione include pagamenti bonus legati a terapie innovative, con chiusura prevista entro il terzo trimestre 2025. A ...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in ...